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Abstract 
Modulation of the inflammatory microenvironment after stroke opens a new avenue for the 
development of novel neurorestorative therapies in stroke. Understanding the spatio-temporal 
profile of (neuro-)inflammatory imaging biomarkers in detail thereby represents a crucial factor in 
the development and application of immunomodulatory therapies. The early integration of 
quantitative molecular imaging biomarkers in stroke drug development may provide key information 
about (i) early diagnosis and follow-up, (ii) spatio-temporal drug-target engagement 
(pharmacodynamic biomarker), (iii) differentiation of responders and non-responders in the patient 
cohort (inclusion/exclusion criteria; predictive biomarkers), and (iv) the mechanism of action. The 
use of targeted imaging biomarkers for may thus allow clinicians to decipher the profile of 
patient-specific inflammatory activity and the development of patient-tailored strategies for 
immunomodulatory and neuro-restorative therapies in stroke. Here, we highlight the recent 
developments in preclinical and clinical molecular imaging biomarkers of neuroinflammation 
(endothelial markers, microglia, MMPs, cell labeling, future developments) in stroke and outline how 
imaging biomarkers can be used in overcoming current translational roadblocks and attrition in 
order to advance new immunomodulatory compounds within the clinical pipeline. 
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Introduction 
Cerebral ischemia is one of the major causes of 
death and disability world-wide due to an overall 
increase in stroke burden. Ischemic stroke represents 
the most prevalent form of stroke [1, 2]. Currently 
available treatment options are limited to tissue 
plasminogen activator (tPA) and endovascular 
treatment after stroke solely aiming at recanalization 
of an occluded vessel [3–5]. Over a thousand 
neuroprotective candidates, targeting different 
parameters of the pathophysiological cascade after 
stroke, have been suggested by preclinical research 
[3]. However, there is a remarkable gap between the 
huge number of candidates and their clinically 
effective translation to stroke patients. The failure of 
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most clinical trials is partially due to the complexity of 
molecular alterations and their kinetics with regards 
to the variety of cell types and molecules and their 
respective functions at different stages after cerebral 
ischemia [6, 7]. Together with the enormous average 
costs of clinical development programs of up to 1.4 
billion dollars [8], there is a need for a refinement of 
preclinical and clinical stroke research [9]. Apart from 
improving quality of research, data acquisition and 
collaborations, novel non-invasive molecular imaging 
biomarkers and techniques may help to overcome the 
translational roadblock in stroke research and to 
facilitate drug development processes [10].  
As current recanalization treatment options are 
limited to the first couple of hours after stroke, there is 
an urgent need for molecular imaging techniques 
employing other markers besides those targeting 
cerebral blood flow, oxygen and glucose 
consumption. Therefore, a rapid imaging workup is 
necessary, and processes like the inflammatory 
response after stroke remain to be investigated as 
these represent a variety of attractive novel targets for 
neurorestorative stroke therapies and extension of the 
therapeutic window. The multi-factorial and 
multi-phasic nature of cerebral ischemia, with an 
initial pro-inflammatory and a delayed repair and 
regeneration phase, emphasizes the intriguing 
possibility to shift the inflammatory response towards 
a pro-resolving, anti-inflammatory phenotype [11, 
12]. The detailed understanding of the dynamics of 
cerebral and peripheral inflammation markers is a key 
step towards the development of next generation 
immunomodulatory therapies for ischemic stroke. 
Molecular imaging combining positron emission 
tomography (PET) and single photon computed 
emission tomography (SPECT) together with 
functional and anatomical imaging by magnetic 
resonance imaging (MRI) in hybrid preclinical and 
clinical scanners represents an important approach to 
decipher these molecular alterations after stroke in a 
spatio-temporal manner. Multi-modality imaging 
bears the advantage of being non-invasive, allowing 
intra-individual follow-up of multiple disease 
processes at a time, while at the same time reducing 
experimental attrition and animal numbers as well as 
increasing statistical power and translatability [13]. 
The superb sensitivity of PET (pico-nanomolar range) 
and SPECT [14, 15] in combination with the fast 
acquisition time, clinical availability and excellent soft 
tissue contrast obtained by MRI, allows for the 
parallel intra-individual determination of various 
parameters after stroke [16]. 
In particular, nuclear imaging techniques like 
PET have been widely used for drug development 
purposes: (i) direct radiolabeling of a new drug 
candidate for distribution (microdosing; <µg), (ii) 
mathematical modeling approaches to decipher 
drug-receptor interactions and subsequent 
assessment of pharmacodynamic responses, (iii) lead 
validation and optimization, (iv) following the 
(patho-)physiological response to a new drug over 
time, (v) allowing early diagnosis, and (vi) following 
longitudinally an imaging biomarker for patient 
monitoring [13, 17–19]. Ideally these imaging 
parameters can be used to enhance our understanding 
of disease pathogenesis and serve as predictive 
biomarkers for patient selection and stratification to 
improve clinical study protocols.  
This review will highlight innovative preclinical 
and clinical imaging biomarkers targeting various 
aspects of neuroinflammation beyond monitoring and 
re-establishing cerebral blood flow (CBF). We will 
highlight their potential use in disease modulation 
and drug development processes towards 
personalized stroke therapies.  
Imaging biomarkers of neuroinflam-
mation 
The lack of blood supply to certain brain regions 
after stroke leads to an orchestrated inflammatory 
response [12]. Resident and peripheral immune cells 
become rapidly activated and peripheral immune 
cells can infiltrate the brain through three major 
routes including (i) direct crossing of the BBB of 
(meningeal) blood vessels, (ii) direct crossing over the 
subarachnoid space into the brain parenchyma and 
(iii) infiltration via the blood-CSF barrier at the 
choroid plexus (Figure 1) [20]. The inflammatory 
response can roughly be divided into an initial 
damaging period with expression and release of 
pro-inflammatory mediators and into a late 
neuroprotective phase of inflammation that is 
hallmarked by release and expression of anti- 
inflammatory mediators [12, 21]. However, Hu and 
colleagues described an increase of anti-inflammatory 
biomarkers a few days after stroke followed by a 
progressive increase of pro-inflammatory markers in 
a mouse stroke model [22]. These contradictory 
results underline the complex overall dynamics, 
heterogeneity and multi-phasic nature of the 
immunological response after stroke making the 
development and application of immunomodulatory 
therapies challenging [12, 21]. This heterogeneity is an 
interesting possibility to extend the therapeutic 
window after stroke [23]. Given the heterogeneous 
location and size of infarctions in the clinical setting, 
the non-invasive assessment of the time course of 
inflammatory parameters by molecular imaging 
(Table 1) may help to investigate the 
pathophysiological response to immunomodulatory 
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therapies in a temporal manner (Table 2). Another 
possible application of molecular imaging is therapy 
selection and patient stratification for immuno-
modulatory treatment, thereby increasing the power 
of a clinical study. 
The following paragraphs will highlight recent 
advances in imaging of several aspects of the 
inflammatory cascade and their use in the 
investigation of treatment responses in preclinical and 
clinical settings. 
 
 
Figure 1. Overview of inflammatory pathways and imaging targets in the CNS and periphery. (A) Interplay between gut and the brain as an important route for 
inflammatory signals from and to the brain influencing stroke outcome. (B) Overview of key infiltration routes of peripheral innate and adaptive immune cells. Peripheral immune 
cells can enter into the ischemic brain from the (i) subarachnoid space (SAS), (ii) direct crossing of the blood brain barrier, and (iii) the choroid plexus across the 
blood–cerebrospinal fluid (CSF) barrier. (C) Dysregulated microbiota and resident intestinal immune cells send inflammatory mediators including cytokines via the 
hypothalamus–pituitary–adrenal glands axis (HPA), the autonomic nervous system, and the enteric nervous system (ENS). (D) Detailed view of the inflammatory events after 
ischemic stroke at the neurovascular unit (NVU) and SAS. CNS-resident microglia and astrocytes become activated and, depending on their polarization state, promote disease 
progression and repair. Resident and infiltrating immune cells exert their bi-modal functions via cell contact-dependent mechanisms and through the action of soluble 
inflammatory mediators. The NVU represents the target structure for functional tissue repair by neuroinflammatory processes. The NVU components may serve as imaging 
targets for the investigation of novel image-guided therapies targeting the rescue of NVU function. 
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Table 1. Selected molecular imaging studies highlighting the dynamics of imaging biomarkers after stroke. 
Marker/Target Imaging 
Modality 
Compound/Tracer Species Occlusion time Peak signal after 
stroke 
Reference 
VCAM-1 MR MPIOs-αVCAM-1 C57BL/6 mice pMCAo and tMCAo 
(various) 
24 hours – 5 days [34] 
P-Selectin MR MPIOs-αP-selectin Swiss mice MCAo and TIA (15 min) 48 hours [40] 
TSPO PET [11C]PK11195 Sprague -Dawley rat tMCAo (1h) 7 days [52] 
TSPO PET [18F]DPA-714 Sprague–Dawley 
rats  
tMCAo (2h) 11 days [53] 
TSPO PET [18F]DPA-714 Sprague–Dawley 
rats  
tMCAo (1.5 h) 7 days [72] 
TSPO PET [18F]DPA-714 C57BL/6 mice tMCAo (30 min) 14 days [60] 
TSPO PET [18F]DPA-714 Balb/c mice tMCAo (60 min) 10 days [70] 
TSPO PET [11C]PBR28 Sprague–Dawley 
rats  
M2Cao (1.5 h) 4-14 days [71] 
TSPO PET [18F]DPA-714 human n.a. n.a. [64] 
cystine-glutamate antiporter (system 
xc-) 
PET [18F]FSPG Sprague–Dawley 
rats  
tMCAo (1.5h) 3-7 days [72] 
α4β2 Nicotinic Acetylcholine Receptor PET 2-[18F]-fluoro-A85380 Sprague–Dawley 
rats  
tMCAo (2h) 7 days [77] 
Matrix metallo-proteinases PET [18F]BR-351 C57BL/6 mice 30 min 7 days [60] 
 
Table 2. Selected studies of anti-inflammatory treatments in stroke and their respective nuclear imaging readouts. 
Drug Target Imaging readout Effect Reference 
Multi-nutrient diet Broad spectrum [18F]DPA-714, DTI, rsfMRI Inflammation ↓, DTI, rsfMRI ↑, functional outcome ↑  [54] 
Minocycline Broad spectrum [18F]DPA-714 and [18F]PBR06 PET, MRI Inflammation ↓, functional outcome ↑ [69, 76] 
sulfasalazine and S-4-CPG inhibition of system xc [18F]DPA-714, [18F]FSPG Inflammation ↓ [72] 
DhβE α4β2 antagonist [11C]PK11195 and 2[18F]-fluoro-A85380 Inflammation ↑ [77] 
AMD3100  CXCR4 antagonist [18F]DPA-714 Inflammation ↓ [70] 
 
Infiltration of immune cells  
Leukocytes are among the first inflammatory 
cells to enter the ischemic brain within hours after 
ischemia and, depending on the animal model, 
infiltration peaks about three days after stroke [6, 7, 
24]. The infiltration of leukocytes depends on 
adhesion markers that are expressed on leukocytes 
and endothelial cells, including P/E-Selectin, ICAM-1 
and vascular cell adhesion molecule 1 (VCAM-1). 
These adhesion markers represent an early and 
essential step in the recruitment of leukocytes into the 
ischemic brain and, therefore, provide an important 
therapeutic target for modulation of leukocyte 
infiltration [25]. 
Beneficial effects of blocking or genetic deletion 
of these adhesion molecules on functional and 
molecular parameters in different animal models of 
ischemic stroke have been studied extensively 
(reviewed by Yilmaz and Granger [25]).  
Several imaging approaches targeting 
intracellular and cell surface markers have been used 
to investigate their temporal expression profile after 
cerebral ischemia (for review: [16, 26, 27]). Among the 
imaging methods for tracking neutrophil recruitment 
to the infarction site, intravital imaging is increasingly 
being used. The applicability of intravital microscopy, 
however, is limited by the invasiveness of the disease 
models, as well as the relatively low temporal 
resolution and translatability into clinical practice 
[28]. Imaging approaches with PET, SPECT, and MRI 
represent imaging techniques with a higher 
translational value due to their non-invasive 
character. 
Most of the imaging paradigms targeting cell 
adhesion markers are based on molecular MRI. 
Molecular MRI utilizes contrastophores (either 
gadolinium- or iron oxide-based) that are linked to a 
protein of interest using a targeting moiety (pharma-
cophore: protein, peptide, antibody or enzymatic 
substrate). Over the last years, micro-sized particles of 
iron oxide (MPIOs) have been shown to possess 
superior characteristics in terms of sensitivity and 
specificity compared to classical ultra-small particles 
of iron oxide (USPIOs) [16, 29]. However, data on the 
application of imaging biomarkers for the assessment 
of treatment efficacy in stroke is still limited. 
VCAM-1 
Several approaches have been undertaken to 
image VCAM-1 expression in infarcted areas [30–32]. 
More recent studies focus on the use of MPIOs 
targeted to VCAM-1. VCAM-1 activation was 
visualized within hours after stroke by MRI and the 
VCAM MPIOs-mediated signal was compared with 
diffusion weighted imaging (DWI). Interestingly, the 
spatial extent of VCAM-1 expression was found to be 
considerably larger than the detectable lesion 
delineated by DWI. The authors concluded that the 
VCAM MPIOs might therefore delineate penumbral 
and core regions of the stroke. Ischemic 
preconditioning was found to significantly reduce 
VCAM MPIOs levels and improved functional 
outcome after stroke [33]. In line with these findings, 
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Gauberti et al. demonstrated spatio-temporal kinetics 
of VCAM-1 surface expression on endothelial cells 
after stroke by using MPIOs conjugated to 
monoclonal VCAM-1 antibodies (MPIOs-αVCAM-1). 
VCAM-1 expression was found perilesional and 
peaked after 24 hours for up to 5 days, depending on 
the severity of the stroke model. The activation of 
VCAM-1 in the periphery suggests that noninvasive 
imaging of this inflammatory reaction could be useful 
to identify the penumbra.  
Interestingly, MPIOs-αVCAM-1 may be used to 
demonstrate the efficacy of immunomodulatory 
therapies with celecoxib and atorvastatin. Both 
compounds reduced VCAM-1 expression in the 
contralateral cortex, but not in the ischemic cortex 
[34]. Results in other disease models including 
Alzheimer’s disease encourage the use of 
MPIOs-αVCAM-1 as an imaging biomarker for 
VCAM-1 expression [35]. To overcome current 
limitations of contrastophores, another study used 
liposomes loaded with the neuroprotectant Citicoline. 
Citicoline has the advantage of inherent chemical 
exchange saturation transfer (CEST) signal, which can 
be detected by MRI. In a targeted theranostic 
approach, Citicoline-loaded liposomes were 
specifically targeted against VCAM-1, leading to 
improved imaging-guided drug delivery to the 
ischemic area in a label-free fashion [36, 37]. However, 
it should be noted that this signal was detected in 
areas of BBB damage, potentially indicating the 
presence of unspecific leakage of liposomes into 
damaged tissue [36]. 
Selectins 
E- and P-selectin expression, as an important 
marker of the tether-roll phase of leukocytes, was 
visualized in vivo by T2-type glyconanoparticle 
reagent GNP-sLex [38]. In this study, E- and P-selectin 
could be visualized by cross-linked iron oxide (CLIO) 
nanoparticles conjugated to anti-human E-selectin 
(CLIO-F(ab')(2)). Interestingly, this study described a 
hypointensity in the T2* area only 3 hours after 
permanent stroke; whereas, this hypointense area 
could only be detected 24 hours after transient 
ischemia. These results underline the sensitivity 
issues related to these techniques. To address this 
issue, paramagnetic gadolinium diethylenetriamine-
pentaacetic acid (Gd-DTPA) conjugated to Sialyl 
Lewis X (Slex) was designed. The authors reported 
improved targeting of the tracer to E- and P-selectin 
mediated by Slex, as it mimics P-selectin glycoprotein 
ligand-1 tetrasaccharide Slex, which mediates the 
binding of leukocytes and platelets to activated 
endothelium [39]. 
Strikingly, antibody-based microparticles of iron 
oxide targeting P-selectin (MPIOs-αP-selectin), similar 
to the previously addressed MPIOs-αVCAM-1 [34, 
35], could be found in mouse brains 24 hours after 
stroke induction. In contrast to MPIOs-αVCAM-1, 
MPIOs-αP-selectin was able to identify and delineate 
transient ischemic attacks (TIA) 24 hours after 
induction. Using these microparticles, the authors 
could discriminate TIAs from epilepsy and 
migraine-mimicking TIAs in the clinical setting [40], 
suggesting sensitivity and specificity of the 
compound for TIAs. 
Despite the high translational value of 
MRI-based assessment of adhesion marker profiles, 
and first successful theranostic approaches, these 
techniques still suffer from various drawbacks, 
including (i) low sensitivity, (ii) low specificity, (iii) 
quantification issues, and (iv) problems with possible 
in vivo toxicity of the molecular imaging marker [34, 
37, 41]. Drug-loaded micelles/liposomes or activat-
able probes based on enzymatic substrates [16, 42] in 
combination with paramagnetic particles may further 
allow the combination of a therapeutic approach with 
improved diagnosis (theranostics) [36, 37, 41].  
Microglia 
Microglia have been implicated as important 
mediators in a variety of diseases. Under physio-
logical conditions, microglia constantly screen the 
brain parenchyma for pathophysiological alterations 
[12, 43]. Under pathological conditions, microglia 
fulfill a dual role. In the acute phase (days) of ischemic 
stroke, microglia produce pro-inflammatory media-
tors such as TNF-α, IL-1β and reactive oxygen species 
(ROS), i.e., proinflammatory M1-like microglia. 
Thereafter, under chronic (days-weeks) conditions, 
microglia obtain an anti-inflammatory M2-like 
phenotype, i.e., anti-inflammatory M2-like microglia. 
The neuroprotective function of these M2-like 
microglia is mediated by the release of IL-10 and 
TGF-β and other growth factors. However, it should 
be noted that the concept of M1 and M2 microglia is 
rather simplified and only represents two aspects of 
microglia polarization, at the same time neglecting a 
variety of different sub-phenotypes [44]. However, it 
has to be pointed out that in chronic post-stroke 
phases inflammation may spread from focal to remote 
areas following Wallerian degeneration and may thus 
not solely be beneficial [45]. Contrarily, it may worsen 
the outcome and lead to cognitive impairment, again 
highlighting the transient function of the inflamma-
tory response. (for review: [46]). 
One important marker of general microglial 
activation (i.e., not function of microglia and 
infiltration of macrophages), is the 18 kDa 
translocator protein (TSPO) located on the outer 
mitochondrial membrane. TSPO is part of 
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mitochondrial permeability transition pore (MPTP) 
and is involved in shuttling cholesterol across the 
mitochondrial membrane and in steroid synthesis 
[47–49]. In the past 30 years, TSPO has become an 
attractive imaging target in neuroinflammation since 
basal expression levels in the brain cells (microglia, 
astrocytes, endothelial and smooth muscle cells, 
subpial glia, intravascular monocytes and ependymal 
cells) are relatively low under physiological 
conditions, while it becomes highly upregulated upon 
neuroinflammatory stimuli in glial cells (microglia 
and astrocytes) and macrophages in different models 
of neurological disease [48–55]. Imaging studies in 
ischemic stroke revealed TSPO to be highly expressed 
by microglia/macrophages in the infarct core, peri- 
infarct areas, as well as in remote areas [45, 56–60].  
TSPO tracers can be subdivided into first and 
second generation tracers. The most prominent first 
generation TSPO ligand is [11C]PK11195. However, it 
suffers from a poor signal-to-noise ratio, and short 
half-life of the 11C-label leading to the development of 
second generation tracers with improved bio-
availability, higher specificity, and favorable signal- 
to-noise ratios. Second generation TSPO tracers like 
[18F]PBR06, [11C]PBR-28, [125I]CLINDE, [18F]GE-180, 
[18F]DPA-714 were used in target validation studies in 
preclinical stroke (Figure 2) [53, 60–63] and clinical 
stroke [64, 65], allowing an improved understanding 
of the spatio-temporal profile of TSPO as an imaging 
biomarker.  
 
 
Figure 2. Investigation of the temporal dynamics of [18F]DPA-714 (TSPO) and [18F]BR-351 (MMPs) uptake after transient middle cerebral artery 
occlusion (tMCAo). (A) The inter-individual comparison highlights differential time-dependent radiotracer uptake patterns. (B) [18F]DPA-714 uptake was significantly increased 
from day 7, peaked at day 14, and was still significantly elevated 21 days after tMCAo. [18F]BR-351 was significantly increased after 24 to 48 hours after tMCAo and 7 days. Data 
are represented as ratio ± SD. (C) Comparison of in vivo PET data with immunohistochemistry for TSPO and MMP-9. Both markers are increased in the infarct zone. Scale bar: 
50 µm. (Adapted with permission from [60], copyright 2015 SAGE Publishing Group). 
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Recently, a third generation of TSPO tracers was 
described. Although a general definition of the 
requirements for a third generation tracer is lacking, 
[11C]ER176 and [18F]GE180 were recently described as 
third generation tracers being less susceptible for the 
rs6971 polymorphism [66–68], However the 
experimental data supporting this is relatively sparse 
[68] or do not fulfill the expectations [67]. 
Application of second generation tracers in 
stroke allowed detection of increased inflammation in 
the infarct region from subacute 3 days post-stroke, 
while the peak of microglia/macrophage response 
was found around 7-14 days after stroke for up to 7 
months post-stroke in remote areas, depending on the 
stroke model in mice and rats (Table 1) [53, 60, 69–73]. 
Especially at late time points after stroke, TSPO- 
positive astrocytes contribute to the amount of 
TSPO-positive cells [53, 71, 74]. Thus, TSPO is a useful 
biomarker of inflammation from sub-acute to chronic 
phases after stroke. 
The knowledge about the spatiotemporal profile 
of TSPO expression was further used to monitor 
therapy effects in experimental stroke for subsequent 
translation (Table 2). Minocycline, a well described 
antibiotic with anti-inflammatory function [75], was 
applied in a rat model of cerebral ischemia. TSPO 
levels, indicated by [18F]DPA-714 PET, were reduced 
in response to minocycline treatment. However, no 
effect on stroke size was observed and functional 
parameters were not obtained [76]. This study 
underlines the still open question of when and how to 
therapeutically interfere with the post-ischemic 
neuroinflammatory cascade to serve a beneficial 
tissue and functional outcome. Another study using 
the PET ligand [18F]PBR06 showed a correlation 
between [18F]PBR06 radiotracer uptake and impaired 
motor function [69]. In contrast to the previous study 
by Martin et al., this group demonstrated treatment 
effects of minocycline through improved motor 
function 22 days after stroke, along with decreased 
[18F]PBR06 uptake after minocycline treatment. 
However, this study involved longer observation 
times and more sophisticated treatment readouts, i.e., 
motor function by rot-a-rod [69]. Domercq et al. have 
further shown that the inhibition of 
Cystine-glutamate antiporter (system xc-) resulted in 
reduced [18F]DPA-714 uptake and microglial M1 
proinflammatory markers 7 days after treatment onset 
(CCL2, TNF and iNOS) [72]. In line with these results, 
treatment with an α4β2 antagonist reduced 
neuroinflammation seven days post stroke in rats, as 
measured with the first generation TSPO tracer 
[11C]PK11195 [77]. The anti-inflammatory effect of 
AMD3100, a CXCR4 antagonist, was evaluated by 
[18F]DPA-714 in a stroke model for up to 16 days after 
stroke induction. In line with previous studies, the 
peak of [18F]DPA-714 uptake was found around 10 
days after stroke. A reduction of [18F]DPA-714 after 
AMD3100 was observed three days after stroke, but 
was not detectable after seven days. No effects on 
functional parameters were investigated [70]. 
Recent studies highlight the potential of novel 
diet-based interventions in a variety of disease models 
[54, 78–83]. In a multicenter study, the potential 
therapeutic use of a multi-component diet enriched 
with, e.g., omega-3 long-chain polyunsaturated fatty 
acids (n3-LCPUFAs), membrane precursors, vitamins, 
and anti-oxidants on several parameters including 
microglia were investigated. The same diet is already 
being applied in the management of patients with 
early Alzheimer’s disease [84, 85]. In order to assess 
the potential treatment effects of this 
multi-component diet, a bi-modal translational 
neuroimaging approach was employed to assess 
treatment effects on perfusion (arterial spin labeling, 
ASL), brain structure (diffusion tensor imaging, DTI) 
and function (resting state functional MRI, rsfMRI), 
inflammation/microglia ([18F]DPA-714 PET) and 
functional parameters (behavioral testing). Interes-
tingly, it could be shown that the multi-component 
diet was able to improve the imaging parameters, as 
well as functional outcome after stroke (Figure 3) [54]. 
The beneficial effects of dietary interventions enriched 
with n3-LCPUFAs may be attributed to different 
metabolites of n3-LCPUFAs, so called pro-resolving 
factors (resolvins). These are able to increase 
phagocytosis and exert anti-inflammatory functions 
on glial cells via peroxisome proliferator-activated 
receptor-γ (PPARγ) modulation, ω-3 FA incorporation 
into the cell membrane, and inhibition of ion currents 
[for review: 62]. Moreover, in preclinical studies, 
docosahexaenoic acid (DHA), an n3-LCPUFA, and its 
oxygenated derivates, docosanoids, have been shown 
to regulate gene expression of inflammatory 
mediators like PPARγ; for further review see [87]. 
These results underline the striking potential of 
dietary interventions in modulation of stroke 
pathogenesis and should be considered for clinical 
translation in the management of stroke patients. 
Notably, microglia/macrophage imaging in 
combination with sophisticated MR neuroimaging 
techniques and ex vivo tissue biomarkers (e.g., 
polarization markers) has proven a powerful tool for 
detection of treatment effects and may serve as a 
blueprint for clinical translation of other 
neuroprotective compounds. 
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Figure 3. [18F]DPA-714 PET in the investigation of diet-mediated immunomodulatory effects on microglial activation. (A) Intra-individual follow up with 
[18F]DPA-714 PET/MRI of mice fed with a control diet (left) versus mice fed with the Fortasyn diet (right). Fortasyn-fed mice showed a reduced uptake of [18F]DPA-714 in the 
infarction after 35 days. (B) Comparison of [18F]DPA-714 with TSPO immunohistochemistry. TSPO levels were reduced in Fortasyn-fed animals (scale bars: 1000 µm and 50 µm). 
(C) TSPO (red) was also expressed by astrocytes (green) 35 days after tMCAo (scale bar: 100 µm). (D) Values represent mean ± SD. [18F]DPA-714 mean uptake ratios were 
significantly reduced from 7 to 35 days after tMCAo in the Fortasyn group when compared to control animals (p<0.029). (E) The maximum [18F]DPA-714 radio uptake ratios 
show reduced [18F]DPA-714 uptake in the Fortasyn diet group from 7 to 35 days (p<0.016). (Adapted with permission from [54], copyright 2017 Ivyspring International 
Publisher). 
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Despite the advances in preclinical microglia 
imaging, clinical data on TSPO in ischemic stroke is 
still relatively sparse. Imaging with the first 
generation TSPO ligand [11C]PK11195 revealed early 
(72 hours post stroke) changes as well as chronic 
changes (up to months) in remote areas, indicative of 
Wallerian degeneration [45, 57, 58, 88, 89]. Besides 
[11C]PK11195, second generation TSPO ligands have 
been used in initial clinical studies. Gulyás and 
colleagues investigated the TSPO signal evolution 
within the ischemic region and peri-infarct regions 
using the second generation TSPO tracer 
[11C]vinpocetine. The authors reported the highest 
radiotracer uptake in the peri-infarct regions 
independent of the time after the insult. However, the 
authors also reported very moderate BPND values for 
[11C]vinpocetine [90]. In another study, the same 
group reported no significant improvements of 
[11C]vinpocetine in comparison to the first generation 
tracer [11C]PK11195 [91]. In a single case study, Kreisl 
et al. found increased binding of [11C]PBR28 after 
subacute infarction [92], but this tracer has not yet 
been used in further stroke research. The fluorine 18 
label of [18F]DPA-714 has the advantage of allowing 
longer scan times and broader clinical availability, as 
evaluated in nine stroke patients. Increased [18F]DPA- 
714 uptake was found within and around the infarct, 
exceeding the blood brain barrier damage, as 
indicated by Gd-enhanced T1-weighted MRI [64]. 
Nevertheless, future studies will have to investigate 
the relative contribution of the BBB damage for 
radiotracer uptake in stroke.  
Using the SPECT TSPO ligand [125I]CLINDE, 
Feng et al. investigated the spatial and temporal 
change of TSPO levels 28 days and 8 months after 
middle cerebral artery stroke. Increased distribution 
volume (VT, in mL cm−3) values were observed mostly 
in peri-infarct areas after 28 days and decreased to 
baseline values after 8 months. Interestingly, 
accumulation of [125I]CLINDE was found in the insula 
of the contralesional hemisphere at this late time point 
[65], indicating the involvement of the entire brain in 
ischemia-induced neuroinflammation. Next to TSPO 
ligands, novel targets for microglia imaging may 
include the 18F-FSPG /system xc- and 
2-18F-fluoro-A85380 (α4β2). Both system xc- and α4β2 
have been reported to be overexpressed in microglia 
after stroke [72, 77]. 
One of the limitations of second generation 
TSPO ligands exacerbating clinical translational 
hurdles is the existence of an rs6971 polymorphism 
within the gene encoding for TSPO that affects the 
binding affinity of TSPO ligands [93–97]. This 
polymorphism results in a non-conservative single 
amino acid substitution from alanine to threonine at 
amino acid residue 147 (Ala147Thr) of the TSPO gene 
causing an inter- and intra-individual variability in 
binding affinity, hampering quantification of imaging 
data [98], while at the same time no effect of 
Ala147Thr on inflammatory and cerebrovascular 
biomarkers was observed [99]. 
Based on the expression of high and low affinity 
sites of TSPO, patients can be subdivided into low-, 
mixed-, and high-affinity binders, whereas different 
ligands display a different sensitivity for the rs6971 
polymorphism [94]. This implicates that the choice of 
the TSPO ligand, as well as the TSPO status of the 
individuals included in a study, may severely 
influence the outcome of the clinical trial. Thus, 
statistical methods accounting for the TSPO status 
and matching of patients should be performed [98]. 
Newly developed third generation TSPO 
ligands, being unsusceptible to the rs6971 
polymorphism, and new non-TSPO molecular 
microglial targets are currently under investigation 
within the EU FP7 program Imaging Inflammation in 
Neurodegenerative diseases (INMiND consortium; 
http://www.uni-muenster.de/InMind/) [100, 101].  
Nevertheless, current second generation TSPO 
ligands are under intense clinical investigation in a 
variety of diseases including Alzheimer’s disease, 
mild cognitive impairment, multiple sclerosis, 
amyotrophic lateral sclerosis, Parkinson’s disease, 
rheumatoid arthritis, brain tumors and alcoholism. 
In conclusion, TSPO imaging provides a 
valuable tool to study the neuroinflammatory 
response in stroke and allows for assessment of 
immunomodulatory treatments targeting inflamma-
tion in pre-clinical and clinical settings. 
Matrix Metalloproteinases (MMPs) 
MMPs belong to the family of secreted or 
membrane-bound zinc- and calcium-dependent 
endopeptidases [102]. Most of the MMPs are secreted 
in their inactive (zymogen) form. After secretion into 
the extracellular space they become rapidly activated 
through proteolytic processing of the cysteine switch 
by plasmin, trypsin, kallikrein, mast cell tryptase and 
other MMPs, as well as ROS and hypochlorous acid 
from inflammatory processes [102–105]. MMPs have 
been implicated in a variety of physiological events 
such as neoangiogenesis, neural plasticity, wound 
healing, tissue remodeling, embryogenesis and 
apoptosis [104, 106]. Besides the physiological 
functions of MMPs, different pathologies have been 
strongly linked to MMP function, i.e., rheumatoid 
arthritis, osteoarthritis, cardiovascular disease, 
fibrosis, tumorigenesis, tumor neovascularization, 
invasion, metastasis, blood brain barrier damage, 
atherosclerosis, multiple sclerosis, meningitis, 
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Alzheimer’s disease, stroke and many more [102, 104, 
107–111]. MMPs contribute to the acute (neuro-) 
inflammatory reaction by modulating the expression, 
activity, and integrity of chemokines, inflammatory 
cytokines, growth factors, and matrix components 
and by affecting receptor turnover and leukocyte 
transmigration (diapedesis) [104, 106, 112, 113].  
In ischemic stroke, MMPs are known to play a 
key role during disease progression. They are 
associated with BBB damage, hemorrhagic 
transformation, and vasogenic edema formation [110, 
114–116]. It should be pointed out that 
over-simplification of MMPs as purely extracellular 
matrix (ECM)-degrading enzymes should be avoided 
since in vivo evidence that MMPs degrade ECM is 
lacking [117]. Several MMPs have been described to 
modulate the inflammatory response in cerebral 
ischemia via a network of complex functions and 
sources, including glial cells and neutrophils as 
important cellular sources. In particular, the 
gelatinases MMP-2 and MMP-9 are elevated after 
cerebral ischemia and have been correlated with BBB 
opening and hemorrhagic transformation [118, 119]. 
Interestingly, early inhibition of MMP-9 activity in 
experimental stroke, as well as genetic knockout, has 
beneficial effects on stroke outcome [120–124]. In 
contrast to acute MMP inhibition, it was shown that 
late inhibition can have detrimental effects, leading to 
increased brain damage characterized by reductions 
in numbers of neurons and newly formed blood 
vessels, supporting the hypothesis of dynamic 
multi-phasic effects of MMPs [119, 125–127]. 
Moreover, it has been reported that MMP 
inhibition leads to reduced migration of doublecortin 
(microtubule-associated protein expressed by 
neuronal precursor cells)-positive cells from the 
subventricular zone to infarcted areas after stroke 
[128]. Problems with the study design, definition of 
endpoints, the design of MMP inhibitors and 
heterogeneous nature of MMPs might so far explain 
the lack of efficacy and adverse effects of MMP 
inhibitors in clinical studies (for review: [129]).The 
multitude of available data on beneficial effects of 
MMP modulation in different disease settings makes 
MMPs attractive as biomarkers and therapeutic 
targets. Thus, there is a strong need for MMP 
inhibitors with increased specificity and selectivity for 
MMP subtypes, as well as sophisticated methods to 
detect MMPs in vivo in real time. 
Most of the currently available preclinical 
imaging probes for tracking MMP activity in stroke 
rely on fluorescently labeled broad spectrum 
inhibitors or activatable (smart) probes. Smart probes 
are designed to remain in a quenched state until the 
quencher is degraded by activated MMPs under 
pathophysiological conditions, resulting in emission 
of near-infrared fluorescence (NIRF) [130]. 
Klohs and colleagues were the first to describe 
the use of an activatable, near-infrared fluorescent 
probe to image general MMP activity after stroke 24 
hours after injection of the tracer. Treatment with the 
MMP inhibitor GM6001 resulted in significantly 
lower tracer signal and lesion volume, suggesting 
successful imaging of in vivo MMP activity [131]. 
Another study made use of MMPsense 750 FAST with 
improved characteristics including a shorter optical 
imaging time for early (within hours) visualization of 
MMP activity. Increased changes in fluorescence 
intensities were found in early ischemic reperfusion 
and at 24 hours post ischemia, but not in sham 
controls. The results correlated with MMP-9 protein 
levels, 5 and 24 hours after ischemia reperfusion. 
Overall MMP activity could be attenuated by 
hypothermia [132]. In contrast to these planar imaging 
approaches, Martín and colleagues further applied 
tomographic optical imaging describing an increase of 
MMP activity as early as 3 to 6 hours correlating with 
the volume of the ischemic damage [133]. Next to 
smart probes, a recent study suggested gelatinase- 
activatable cell-penetrating peptides (ACPP) with a 
cleavable l-amino acid linker linked to Cy5 or 
gadolinium for imaging MMP activity and therapy 
response in ischemic tissue in the femtomolar range 
[134]. These studies emphasize the potential of in vivo 
assessment of MMP activity after stroke and 
investigation of therapy response. The drawback of 
both probes is, however, the relatively long 
circulation required before imaging and/or the 
relatively low signal intensities due to physical 
limitations due to tissue scattering and limited 
penetration depth of light, requiring invasive 
measurements [131, 132]. To address this, the probe 
MMP-P12 with improved characteristics including 
optimized stability, blood half-life and enzyme 
susceptibility was developed. The probe allowed 
observation of significant signal enhancement from as 
early as 15 minutes to 24 hours after injection, with a 
peak 1 hour after injection. The spatiotemporal signal 
was followed for up to 14 days after stroke. Treatment 
with the MMP inhibitor GM6001 reduced the 
MMP-P12 fluorescence signal, suggesting MMP 
substrate specificity, though no complete blocking of 
the signal was observed. The feasibility of using this 
probe for drug development purposes was further 
tested by treating mice with RWJ67657, an inhibitor of 
the p38 mitogen-activated protein kinase (MAPK) 
signaling pathway, which resulted in modulation of 
MMP activity after stroke accompanied by improved 
functional outcome. Moreover, p38 MAPK inhibition 
rescued MMP-P12 NIRF intensity [130]. A direct 
 Theranostics 2018, Vol. 8, Issue 10 
 
 
http://www.thno.org 
2613 
comparison of NIRF probes is difficult due to the 
differences in stroke models being used and the 
different imaging time points. Despite the various 
advantages of NIRF imaging for real-time 
visualization of MMP activity in preclinical drug 
discovery including high sensitivity, low cost, 
non-ionizing radiation and vast applicability [135], 
there is a lack of clinical translatability due to the 
physical limitations of light only allowing for 
intra-operative applications. 
Another important step towards clinical 
translation is the use of radioactively labeled 
compounds for nuclear imaging applications. The 
first radiofluorinated hydroxamate-based MMP 
inhibitor, the I-2-(N-benzyl-4-(2-[18F]fluoroethoxy) 
phenylsulphonamido)-N-hydroxy-3-methylbutanami
de compound CGS 27023A 1 ([18F]BR-351), was 
developed by Wagner and colleagues. Due to the 
underlying radiochemistry, [18F]BR-351 can only bind 
the activated forms of MMP-2 (IC50 = 4 nM), -8 (IC50 
= 2 nM), -9 (IC50 = 50 nM), and -13 (IC50 = 11 nM) 
[136]. 
In a multi-tracer study [18F]BR-351 was used in 
combination with the TSPO ligand [18F]DPA-714 for 
spatio-temporal assessment of MMP activity in a 
murine model of ischemic stroke (Figure 2) [60]. 
Interestingly, MMP expression, as measured by 
[18F]BR-351, appeared already 24 hours after tMCAo, 
peaked at 7 days post stroke, and was only seen in a 
subset of mice at later time points (14-21 days post 
stroke) [60]. Although this study did not focus on 
targeted MMP therapy, the results raise the intriguing 
possibility that [18F]BR-351 might be useful in 
selecting individuals who may benefit from MMP 
inhibitory therapy. Future studies should focus on 
how radioligands like [18F]BR-351 can be used to 
select and assess MMP-based therapies in stroke. 
Encouraging results come from a recent clinical study 
in patients with multiple sclerosis where [18F]BR-351 
was successfully applied to monitor the early signs of 
multiple sclerosis and for monitoring anti- 
inflammatory treatment, thus opening new avenues 
for personalized therapies [137]. 
The combination of longitudinal MMP imaging 
in conjunction with improved inhibitors, which 
selectively modulate MMPs, is needed to rejuvenate 
the idea of using MMP modulation as a personalized 
therapy approach after stroke. 
Cell-based therapies and in vivo cell 
tracking 
Molecular imaging has been applied to track 
different cell populations after stroke. This is 
important to improve our understanding of the 
spatiotemporal immune cell infiltration and activation 
after cerebral ischemia. One example is the early 
clinical study by Price et al. [138], in which migration 
of [111In]troponin-labeled neutrophils in stroke 
patients was successfully tracked by gamma 
scintigraphy. Additionally, molecular imaging 
provides a powerful tool to evaluate the success of 
(stem) cell-based therapies, aiming to stimulate tissue 
repair after stroke. Investigated cell types showing 
promising therapeutic success in preclinical studies 
include, but are not limited to, neural stem cells 
(NSCs) [139], mesenchymal stem cells (MSCs) [140] 
and bone marrow mononuclear cells (BMMNCs) 
[141]. Interestingly, the reported success of those 
therapies is attributed to paracrine effects rather than 
to the replacement of destroyed neurological tissue. 
Observed effects include increased neurological 
plasticity [142] and stimulation of angiogenesis and, 
therefore, revascularization of the ischemic tissue 
[143–147]. Another important mode of action is 
immunomodulation induced by the transplanted 
cells. Brenneman et al. showed a downregulation of 
inflammatory cytokines in the brains of rats treated 
with BMMNCs as well as upregulation of Il-10 in 
acute stroke [148]. Yoo et al. reported immune 
suppression via TGF-β produced by transplanted 
MSCs themselves [149]. Interestingly, the immuno-
modulatory effects were systemic rather than 
restricted to the brain, possibly explaining why 
intravenous application of stem cells has therapeutic 
effects, even though only very few cells reach the 
brain [140, 150]. Next to MSCs and BMMNCs, 
specialized regulatory B- and T-lymphocytes may also 
importantly contribute to therapeutic capacity in 
ischemic stroke and should be pursued as imaging 
and therapeutic targets (for review: [151]).  
Non-invasive imaging is ideally suited to 
investigate the migration and engraftment of 
transplanted cells. For all, direct or indirect labeling of 
the transplanted cells is necessary. Long term tracking 
and engraftment of transplanted MSCs or BMMNCs 
has been successfully conducted in animal models 
and first human stroke patients using the SPECT 
tracers [99mTc]HMPAO and [111In]Oxine [152, 153] as 
well as small iron oxide-based agents such as 
SPIO-based particles for MRI [154, 155]. The severe 
limitation of direct labeling approaches for both 
nuclear imaging as well as MRI is the low retention 
rate and accompanied tracer leakage from the 
transplanted cells [156, 157]. In the case of SPIOs, 
leaked particles can be taken up by phagocytic cells in 
the ischemic area and might result in positive signals 
in the absence of transplanted cells [156]. 
Alternatively, cells can be labeled indirectly, e.g., by 
using reporter genes that are only expressed by 
transplanted cells [158]. Bioluminescence imaging 
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(BLI) has been applied to visualize and monitor 
endogenous stem cell vitality and response post 
stroke [159] and to image the fate of fluc-transduced 
MSCs [157, 160], NSCs [159] and monocytes/ 
macrophages [161]. BLI is limited by the low 
penetration depth of light and, while visualization of 
cells through the skull is possible, imaging remains 
restricted to surface structures. Genetic reporters have 
also been investigated for tracking of cells using 
nuclear imaging. The best characterized reporter is 
based on the herpes simplex virus type 1 thymidine 
kinase (HSV-1-tk) that can phosphorylate isotope- 
labeled pyrimidine analogs like [124I]FIAU or 
[18F]FHBG and thereby trap them in transplanted cells 
[162]. Severe disadvantages of the HSV-1-tk-system 
are possible immune reactions against the viral 
protein and the relatively low blood brain barrier 
penetration of the applied imaging probes [163]. A 
promising alternative is the human sodium iodide 
symporter (hNIS) that can transport all radioactive 
forms of I−. While hNIS so far has not been applied 
after stroke, it has been successfully used to track 
MSCs, for example, in animal models of breast cancer 
[164], glioma [165] and myocardial infarction [166]. 
Similarly, indirect labeling of cells, e.g., via reporters 
based on CEST, has been investigated for tracking 
cells by MRI [167]. However, to date this approach has 
not been applied to track cells after cerebral ischemia.  
Novel imaging approaches will focus not only 
on tracking the fate of transplanted cells, but at the 
same time monitoring therapy responses in the form 
of immunomodulation, changes in the microenviro-
nment and activation of endogenous neural stem 
cells. In a promising approach Daadi et al. applied 
longitudinal multimodal imaging to track NSCs 
labeled both directly (SPIOs for tracking with MRI) 
and indirectly (HSV-1-tk reporter for PET imaging 
with [18F]FHBG) [168]. They elegantly combined 
tracking of grafted cells with analysis of infarct size by 
MRI and neurological metabolic activity by 
[18F]FDG-PET over the course of several months. In 
the future, multimodal- and multitracer imaging 
assessing microglia and tissue remodeling, in 
combination with cell tracking will help to monitor 
immunomodulation and changes in brain 
microenvironment [60]. In addition, monitoring of 
endogenous neural stem cells, for example by 
3’-deoxy-3’-[18F]fluoro-L-thymidin ([18F]FLT) -PET, 
could elucidate reparative processes induced by stem 
cell therapies. Rueger et al. applied [18F]FLT to 
monitor endogenous NSC proliferation in the 
subventricular zone following minocycline treatment 
in rats with cerebral ischemia [169]. In this 
multimodal- and multitracer imaging study, [18F]FLT 
imaging was combined with [11C]PK11195-PET to 
assess neuroinflammation and MRI to monitor infarct 
size. 
Future perspectives 
Imaging the brain-gut axis  
Investigation of the role of intestinal microbiota 
in neurological diseases and recovery has drawn a lot 
of attention for microbiota as possible disease- 
modulating entities in stroke (for review: [170, 171]). 
Immune cells, hormones and neurotransmitters 
originating from the gut may reach the brain via a 
recently discovered lymphatic subsystem, which 
allows for direct or indirect transport of inflammatory 
mediators from the gut to the brain (Figure 1). This 
specialized lymphatic system drains from the 
cerebrospinal fluid in the adjacent subarachnoid space 
and the interstitial fluid to the deep cervical lymph 
nodes and may be visualized by molecular imaging 
[172–174].  
Another aspect of intestinal microbiota is their 
role in regulating the permeability of the BBB. 
Germ-free animals have been shown to exhibit 
reduced expression levels of tight junction proteins, 
which results in increased permeability of the BBB for 
molecules [174–176]. In line with these observations, 
complete depletion of gut microbiota with a 
broad-spectrum antibiotic cocktail led to increased 
mortality rates and development of severe colitis in a 
mouse model of stroke [177]. 
In response to stroke stages, various reports 
exemplify significant changes in the composition of 
gut microbiota in preclinical and clinical stroke that 
partially correlate with disease severity [178–181]. 
This raises the intriguing possibility of selective 
modulation of the gut microbiome to treat stroke. In 
line with this notion, beneficial effects on stroke 
severity were observed by therapeutic transplantation 
of fecal microbiota partially restoring bacterial species 
diversity and improving stroke outcome likely via a 
lymphocyte-dependent mechanism [179]. Further 
evidence for a link between microbiota and the 
lymphocytic response after stroke was deduced by 
studies of Benakis and colleagues. They induced 
microbiota dysbiosis by antibiotic treatment, which 
led to an increase in regulatory T cells, suppression of 
IL-17-positive γδ T cells and thus reduced trafficking 
of effector T cells from the gut to the leptomeninges 
after stroke, resulting in smaller infarcts and 
improved behavioral outcome [182]. Little is known 
about the in vivo dynamics of specialized gut 
microbiota and trafficking cells (i.e, lymphocytes) 
after stroke. Therefore, the in vivo follow-up by 
molecular imaging of bacterial dysbiosis and 
trafficking cells may have strong indications in patient 
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stratification and selection for therapy. Novel imaging 
agents are needed to study gut microbiota 
non-invasively over time. 
Imaging astrocytes: 
Astrocytes are the key cells within the 
neurovascular unit mediating exchange of signals 
between the vascular system and neurons and are an 
important mediator of damage and repair after stroke 
[183–185]. As for many other immune cells, astrocytes 
also have detrimental functions through hyper-
reactivity and glial scar formation, as well as 
beneficial functions through neuroprotective, 
angiogenic, immunomodulatory, neurogenic, and 
antioxidant functions (for review: [186]). Therefore, 
astrocytes also represent an important therapeutic 
and thus imaging target. Despite encouraging data on 
monoamine oxidase B (MAO-B) binding PET ligands 
like [11C]deuterium-L-deprenyl (DED) in Alzheimer’s 
disease [187, 188], in vivo imaging data on astrocyte 
distribution and activity after stroke still represents an 
underexplored aspect of the disease. Besides DED, 
TSPO and α4β2 nicotinic acetylcholine 
receptor-targeted PET ligands are able to visualize 
astrocytic activation, depending on the imaging time 
point after stroke [54, 77, 189]. Nevertheless, there is 
still a need for more specific astrocytic imaging 
biomarkers with longer half-life isotopes for 
monitoring disease progression and therapy 
responses. 
Discussion 
Multi-modality and multi-tracer imaging have 
the potential to support drug development processes 
by answering key questions about location, extent, 
temporal profile, and therapy effect on an imaging 
biomarker after stroke, thereby facilitating our 
understanding of disease progression. By simul-
taneously providing profiles of different markers after 
stroke, multi-modality and multi-tracer imaging can 
assist in development, selection, application and 
follow-up of targeted therapies for stroke patients at 
specific time-points (personalized medicine). These 
types of technologies are important, especially in 
diseases such as stroke with its highly dynamic 
disease process and with heterogenous and variable 
molecular signatures within different parts of the 
diseased brain.  
Current imaging paradigms aim at identifying 
the location and extent of the stroke lesion, estimation 
of the penumbra and patient selection for 
recanalization therapy. CT and several MRI 
techniques are used to obtain physiological data and 
to exclude hemorrhagic transformation [190, 191]. 
However, next to physiological and anatomical 
information, molecular parameters are important for 
targeted and personalized therapies. This review was 
not dedicated to pathophysiological and molecular 
markers such as cerebral blood flow, oxygen and 
glucose consumption, but on imaging biomarkers that 
may allow the assessment of further consequences 
after stroke such as neuroinflammatory and tissue 
repair processes. Current tracers fall short in 
discriminating between different inflammatory cell 
types and/or polarization states. Thus, further 
imaging biomarkers and novel techniques, e.g., 
optogenetics, specifically targeting these differences 
in cell activation and function need to be developed 
and are currently under evaluation [72, 77, 100]. 
Ideally, these novel markers should be longitudinally 
studied (intra-individual imaging) and combined 
with, e.g., other imaging and molecular techniques 
including “-omics” and liquid biopsies to obtain a 
patient-specific detailed characterization of disease. 
This will allow stratification of patients for treatment 
and drug development paradigms. As target 
availability and resulting patient stratification is a key 
determinant of sample sizes in clinical trials, 
molecular imaging will provide important 
information to determine sample sizes and to define 
inclusion and exclusion information earlier than 
standard clinical assessments and at the same time 
increase the sensitivity and predictivity of clinical 
studies [192]. 
In parallel with defining new imaging targets, 
innovative disease-resolving and neurorestorative 
therapies need to be developed. These may include 
immunomodulatory therapies, dietary interventions 
and related alterations of the microbiota-gut-brain 
axis [82, 193].  
Despite the multitude of advances in imaging- 
guided therapies, there is still a strong need to further 
improve the quality of research to obtain predictive 
and clinically translatable data. To this end, research 
activities should involve collaborative community 
efforts, including multi-center studies as suggested 
[10, 194] and applied recently [54, 195–198]. The 
concept of reverse-translating quality standards from 
clinical studies into preclinical work has shown 
promise and overall acceptance to further enhance 
translatability of research [199]. 
Next to general quality measures in stroke 
research, imaging research must overcome additional 
issues specific to the field. Obtaining meaningful, 
quantifiable data remains an important challenge in 
preclinical and clinical research. Nuclear imaging 
techniques provide the essential pharmacodynamic 
data of radiolabeled compounds, but they also need to 
be harmonized [200–202]. In particular, quantification 
in small animals remains challenging, since 
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pharmacokinetic/pharmacodynamic modeling usual-
ly requires determination of an arterial input function 
by repeated blood sampling. The choice of the right 
mathematical model, either model- or data-based, 
applied for determination of transfer rate constants, 
volumes of distribution or binding potentials may 
also vary between different ligands and targets [201, 
202]. This problem can be exemplified by means of 
TSPO tracer studies, which suffer from a lack of a 
suitable reference region in the brain. Multiple 
approaches have been undertaken to overcome these 
limitations to create parametric images including 
population-based approaches, Logan analysis and 
spectral analysis [203–205].  
In summary, over the last couple of years, the 
molecular imaging field has rapidly evolved and 
many novel approaches to dissect molecular 
processes over time and during the course of a disease 
process in various tissue compartments in vivo are 
under way. Molecular imaging will therefore 
represent an important asset to the drug development 
process by providing essential information about 
patient-specific disease progression and therapy 
response, while allowing for patient selection, 
stratification and personalized therapy. 
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